Immutep reports success in soft tissue sarcoma trial
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ImmuPharma PLC (IMM)
ImmuPharma PLC stock price live, this page displays LON IMM stock exchange data. View the IMM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ImmuPharma PLC real time stock price chart below.
What Is the ImmuPharma PLC Stock Price Today?
The ImmuPharma PLC stock price today is 1.58.
What Is the Stock Symbol for ImmuPharma PLC?
The stock symbol for ImmuPharma PLC is ""IMM.""
What Stock Exchange Does ImmuPharma PLC Trade On?
ImmuPharma PLC is listed and trades on the London stock exchange.
Is ImmuPharma PLC a Good Stock to Buy?
Determining whether ImmuPharma PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMM quote. (ISIN: GB0033711010)
What Is the ImmuPharma PLC Stock Price Today?
The ImmuPharma PLC stock price today is 1.58.
What Is the Stock Symbol for ImmuPharma PLC?
The stock symbol for ImmuPharma PLC is ""IMM.""
What Stock Exchange Does ImmuPharma PLC Trade On?
ImmuPharma PLC is listed and trades on the London stock exchange.
Is ImmuPharma PLC a Good Stock to Buy?
Determining whether ImmuPharma PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMM quote. (ISIN: GB0033711010)
London
Currency in GBP
1.58
-0.13(-7.59%)
Closed·
Fair Value
An estimate of a ImmuPharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.58
1.68
52 wk Range
0.85
7.26
IMM Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
IMM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a ImmuPharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.581.68
52 wk Range
0.857.26
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
IMM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a ImmuPharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Immutep Quarterly Activities Report Q3 FY25
- Investing.com
- Immutep reports success in soft tissue sarcoma trial
- Investing.com
- Immutep Quarterly Activities Report Q3 FY25
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
ImmuPharma PLC Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Compare IMM to Peers and Sector
Metrics to compare | IMM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −0.6x | −0.5x | |
PEG Ratio | 0.05 | −0.05 | 0.00 | |
Price/Book | 23.5x | 1.6x | 2.6x | |
Price / LTM Sales | - | 2.1x | 3.3x | |
Upside (Analyst Target) | - | 71.9% | 43.5% | |
Fair Value Upside | Unlock | 8.9% | 6.8% | Unlock |
Earnings
Latest Release
May 22, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
-- / --
FAQ
What Stock Exchange Does ImmuPharma Trade On?
ImmuPharma is listed and trades on the London Stock Exchange stock exchange.
What Is the Stock Symbol for ImmuPharma?
The stock symbol for ImmuPharma is "IMM."
What Is the ImmuPharma Market Cap?
As of today, ImmuPharma market cap is 7.90M.
What Is ImmuPharma's Earnings Per Share (TTM)?
The ImmuPharma EPS (TTM) is -0.01.
When Is the Next ImmuPharma Earnings Date?
ImmuPharma will release its next earnings report on 24 Sept 2025.
From a Technical Analysis Perspective, Is IMM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has ImmuPharma Stock Split?
ImmuPharma has split 0 times.
How Many Employees Does ImmuPharma Have?
ImmuPharma has 6 employees.
What is the current trading status of ImmuPharma (IMM)?
As of 09 Aug 2025, ImmuPharma (IMM) is trading at a price of 1.58, with a previous close of 1.71. The stock has fluctuated within a day range of 1.58 to 1.68, while its 52-week range spans from 0.85 to 7.26.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.